Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz To Close Barcelona Plant Under Antibiotics Manufacturing Revamp

Novartis Division Also Reveals Plans For Expansion

Executive Summary

Sandoz has shed some light on how it intends to invest €150m into its European antibiotics manufacturing network, while announcing the closure of a plant in Spain to remain “cost-competitive on the global market.”

You may also be interested in...



Sandoz To Pump Another €50m Into Kundl Antibiotics Site

To increase manufacturing capacity for finished dosage form penicillins, Sandoz is investing another €50m into its key antibiotics site in Kundl, Austria. But the company feels that fundamental reforms are needed from regulators to ensure the long-term sustainability of European-based antibiotic manufacturing and supply.

Sandoz ‘Bucks Trend’ With Completion Of GSK Cephalosporins Deal

Sandoz has completed the acquisition of GSK’s cephalosporin antibiotics business which includes the Zinnat, Zinacef and Fortum brands in more than 100 markets. Commenting as the deal closed, Sandoz CEO Richard Saynor emphasized the importance of investing in antibiotics. 

Sandoz Champions Stability As It Returns To Growth In Q2

Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel